SkyGem Acquisition Limited has announced an unconditional mandatory cash offer for Allergy Therapeutics PLC. The Offer Document, which contains the full terms and conditions of the offer and the procedures for acceptance, has been published and sent to Allergy Therapeutics shareholders and persons with information rights. Under the terms of the offer, Allergy Therapeutics shareholders will receive 1 pence in cash for each Allergy Therapeutics share. The cash consideration implies a value of approximately £47.91 million for the issued and to be issued share capital of Allergy Therapeutics. The offer represents a discount of 23% to the closing price of 1.30 pence per share on October 18, 2023, and a discount of 84% to the closing price of 6.25 pence per share on April 5, 2023. Shareholders are advised to review the Offer Document and seek independent financial advice before making a decision on whether to accept the offer. The offer can be accepted by completing and returning the Form of Acceptance, along with share certificates and/or other documents of title, to the Receiving Agent by November 9, 2023. Uncertificated shares can be accepted electronically through CREST. Shareholders who are unsure of the acceptance procedure can contact the Receiving Agent or their CREST sponsor for assistance.